Who makes Cenegermin Ophthalmic Solution [Oxervate]?

Cenegermin Ophthalmic Solution [Oxervate] is developed by Toyos Clinic.

What development phase is Cenegermin Ophthalmic Solution [Oxervate] in?

Cenegermin Ophthalmic Solution [Oxervate] is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

Cenegermin Ophthalmic Solution [Oxervate]

Toyos Clinic · FDA-approved active Small molecule Quality 2/100

At a glance

Generic name	Cenegermin Ophthalmic Solution [Oxervate]
Sponsor	Toyos Clinic
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Cenegermin Ophthalmic Solution [Oxervate] CI brief — competitive landscape report
Cenegermin Ophthalmic Solution [Oxervate] updates RSS · CI watch RSS
Toyos Clinic portfolio CI